Form 4: BioMarin Director Maykin Ho Acquires 6,650 Shares of Common Stock
SEC Form 4 Filing
Director Maykin Ho acquired 6,650 shares of BioMarin Pharmaceutical Inc. common stock on May 20, 2025, through restricted stock units.
Summary
- On May 20, 2025, Maykin Ho, a director of BioMarin Pharmaceutical Inc., acquired 6,650 shares of common stock.
- The acquisition was in the form of restricted stock units.
- Following the transaction, Maykin Ho beneficially owns 28,010 shares of BioMarin common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock acquisition by a director.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.
Stakeholder Impact
- The acquisition of shares by a director can be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 05/20/2025 | Date of transaction: Acquisition of 6,650 shares of common stock via restricted stock units. |
| 05/22/2025 | Date of signature on the Form 4 filing. |
Keywords
BioMarin, BMRN, Maykin Ho, Director, Stock Acquisition, Restricted Stock Units, Form 4, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.